Date and Time: Thursday 17th February 2011, from 1000 until 1630

Minutes: Confirmed

Guideline Development Group Meeting 2: Management of psoriasis

 Place:
 Royal College of Physicians, 11 St Andrews Place, Regent's Park, London

 NW1 4LE
 NW1 4LE

Present:	Catherine Smith (Consultant Dermatologist and Senior Lecturer, Chair) Paul Hepple (General Practitioner) Jillian Peters (Dermatology Nurse Practitioner) Karina Jackson (Nurse Consultant, Dermatology) Ruth Murphy (Adult and Paediatric Dermatology Consultant) Richard Warren (Senior Clinical Lecturer and Honorary Consultant Dermatologist) Roderick Turner (Community Pharmacist) David Chandler (Patient member) Christine Bundy (Invited expert, Senior Lecturer in Psychological Medicine/ Health Psychology) Jill Parnham (Guideline Operations Director, NCGC) Bernard Higgins (Clinical Director, NCGC) Laura Sawyer (Senior Health Economist, NCGC) Rachel O'Mahony (Senior Research Fellow, NCGC) Ellie Samarasekera (Research Fellow, NCGC) Silvia Rabar (Project Manager, NCGC) Jill Cobb (Information Scientist, NCGC present for item 5)
Apologies:	Natasha Smeaton (General Practitioner) Claire Strudwicke (Patient member)

In attendance:

NICE Staff:		
NICE attendee 1	Sarah Dunsdon (Guidelines Commissioning Manager)	From item 3 onwards

Observers:

Observer 1	Kate Kelley (Guidelines Manager, NCGC)	
Observer 2	Rachel Holmes (Research Fellow, NCGC)	

Notes

1. Welcome and declarations of interest

The chair welcomed the group to the second psoriasis guideline development group meeting. Apologies were received from Natasha Smeaton and Claire Strudwicke.

The chair requested updates to the existing declarations of interest from GDG members. No new interests were declared. Two GDG members declared interests between GDG1 and GDG2. Christine Bundy declared a personal pecuniary interest and a personal non-pecuniary interest. Karina Jackson declared two personal pecuniary interests.

The register of declarations of interest was made available to the GDG chair. The chair reviewed the declarations of interest and deemed that none were in conflict with the agenda topics and clinic questions under discussion at the meeting.

2. First review question for GDG2

The GDG discussed the evidence for tools to assess severity and impact of psoriasis.

3. Health economic prioritisation

The group discussed and agreed which questions would be a high priority for original health economic modelling.

4. Second review question for GDG2

The group discussed the evidence for risk factors for hepatotoxicity in people with psoriasis who are taking methotrexate.

5. Review protocols and outcome measures for review

The group discussed the outcome measures that would be used for evidence reviews.

6. Review minutes of GDG1

The minutes were agreed to be a true and accurate record of the meeting.

7. Any other business None

8. Summary of next steps

The Chair thanks the GDG members for attending and outlined the work plan for GDG3.

Date, time and venue of the next meeting

Date and time: Thursday 17th March from 1000 until 1630 Venue: Boardroom, National Clinical Guideline Centre, 5th Floor, 180 Great Portland Street, London W1W 5QZ